GSK's RSV vaccine accepted for regulatory review by EMA

(Sharecast News) - Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older. The FTSE 100-listed group noted that Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk for RSV disease.

GSK said a European regulatory decision was expected to be reached during H126 and stated it was continuing to seek expanded indications for its RSV vaccine in other countries, including the US and Japan.

As of 0715 BST, GSK shares were untraded at 1,554.0p.





Reporting by Iain Gilbert at Sharecast.com